Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | EPHB4 | P54760 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.30 |
| ▸ | BAZ2B | Q9UIF8 | 2/20 | 0.30 |
| ▸ | CCR9 | P51686 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3297345 | 0.90 | ACLY (0.36) | ACLYS1PR1MAPTGAAMAPK1 | |
| SCHEMBL3298548 | 0.90 | DGAT1 (0.33) | — | |
| SCHEMBL3302802 | 0.89 | ACLY (0.40) | ACLYS1PR1MAPTGAAMAPK1 | |
| SCHEMBL3298201 | 0.89 | SMN1; SMN2 (0.34) | PIK3CAMAPK1SMN1; SMN2 | |
| SCHEMBL3295496 | 0.89 | CCR9 (0.35) | ACLYPIK3CAMAPTSMN1; SMN2CCR9 | |
| SCHEMBL3301412 | 0.88 | KDM4E (0.36) | ACLYL3MBTL1CCR9 | |
| SCHEMBL3298932 | 0.86 | IRAK4 (0.31) | — | |
| SCHEMBL3301125 | 0.85 | ROCK1 (0.34) | CCR9 | |
| SCHEMBL3297377 | 0.85 | ROCK1 (0.32) | — | |
| SCHEMBL3302071 | 0.85 | IRAK4 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093703-A1 | SUBSTITUTED ARYLSULPHONYLGLYCINES, THE PREPARATION THEREOF AND THE USE THEREOF AS PHARMACEUTICAL COMPOSITIONS | PYGL, PYGM, G6PC1 | ACLY 297/4885S1PR1 2168/4885EPHB4 3888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.